📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

End-of-Phase-2 Briefing Book (OBX-319)

Document ID: MTG-EOP2
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): FDA meetings

End-of-Phase-2 Meeting Briefing Book — OBX-319

End-of-Phase-2 briefing for OBX-319: the Phase 2 results, the proposed pivotal design and endpoints for OBX319-301, statistical and estimand strategy, and the safety-database plan, with questions to align the registration program.

1. Purpose of the Meeting and Requested Outcomes

Virtual Biopharma Inc. requests an End-of-Phase-2 meeting to reach agreement with the Agency on the design and analysis of the proposed single pivotal Phase 3 study, OBX319-301, in adults with moderate-to-severe active Systemic Lupus Erythematosus (SLE), and on the overall content of the planned Biologics License Application (BLA) to be submitted under 21 CFR Part 601. The specific outcomes sought are: (i) concurrence that the completed nonclinical and Phase 1/2 program adequately supports the proposed confirmatory study; (ii) agreement on the primary endpoint, estimand framework, and multiplicity control; (iii) agreement on the size and duration of the pre-marketing safety database for a chronically administered B-cell-depleting biologic; and (iv) alignment on the immunogenicity, clinical-pharmacology, and CMC expectations specific to a CHO-derived bispecific monoclonal antibody. The questions on which decisions are requested are consolidated in Section 11.

The information in this package is intended to be sufficient for the Agency to provide advice; the Sponsor requests written responses in advance of the meeting and will confirm which questions remain for discussion.

2. Product Description and Mechanism of Action

OBX-319 is a humanized, bispecific IgG1 monoclonal antibody that simultaneously engages CD19 and CD20 on the surface of B lineage cells, produced by recombinant Chinese Hamster Ovary (CHO) cell culture and administered subcutaneously. The molecule retains a functional human IgG1 Fc domain, and depletion of target-bearing cells is mediated by the established Fc effector mechanisms (antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity) together with direct engagement of the two antigens.

The dual-targeting rationale is central to the development hypothesis in SLE. CD20 is expressed from the pre-B through the mature/memory B-cell stages but is lost on plasmablasts and plasma cells, whereas CD19 is expressed across a broader window of B-cell ontogeny, including CD20-low/negative plasmablast populations implicated in autoantibody production. By co-engaging both antigens, OBX-319 is designed to achieve deeper and more uniform depletion of the pathogenic B-cell compartment than single-antigen targeting, and to reach cells that can escape a CD20-only agent. The intended clinical consequence is a reduction in autoantibody-secreting cells and in downstream immune-complex-mediated tissue injury that drives SLE disease activity.

The proposed presentation is a subcutaneous formulation intended for administration as High and Low dose levels, supporting a fixed-dose, at-home or clinic administration paradigm consistent with chronic use in an outpatient autoimmune population.

3. Regulatory History and Development Status

The IND for OBX-319 is active. Development to date comprises a completed nonclinical package (Module 4), a first-in-human single- and multiple-ascending-dose program, and a Phase 2 dose-ranging study in moderate-to-severe active SLE. The Sponsor is separately evaluating expedited program eligibility on the basis of the unmet need in SLE and the depth and durability of the pharmacodynamic effect observed to date. This End-of-Phase-2 interaction is intended to precede initiation of the pivotal study OBX319-301 and to finalize the elements of the confirmatory package required for the BLA.

4. Nonclinical Program Summary

The nonclinical program was designed in accordance with ICH S6(R1) for biotechnology-derived pharmaceuticals and ICH M3(R2), with reproductive and developmental assessment per ICH S5(R3) and safety pharmacology endpoints integrated into the repeat-dose toxicology per ICH S7A.

Species selection: OBX-319 binds human CD19 and CD20 epitopes and does not cross-react with rodent orthologues; the cynomolgus monkey is the sole pharmacologically relevant species, in which both target antigens are engaged and the pharmacology (peripheral and tissue B-cell depletion) is recapitulated. Consistent with ICH S6(R1), the toxicology program was therefore conducted in a single relevant species (cynomolgus monkey), supported by tissue cross-reactivity assessment. Repeat-dose studies characterized the expected, exaggerated-pharmacology finding of sustained B-cell depletion and its reversibility on recovery, with safety margins expressed as the ratio of systemic exposure (AUC/Cmax) at the No-Observed-Adverse-Effect Level to the projected human exposure at the clinical dose levels.

Studies that are not scientifically warranted for a large-molecule monoclonal antibody were not conducted, and the Sponsor requests confirmation of this position: standard genotoxicity testing (ICH S2) is not applicable to a proteinaceous therapeutic; a dedicated carcinogenicity program (ICH S1) is not warranted, with carcinogenic potential instead addressed by a weight-of-evidence assessment of the immunomodulatory mechanism; and in vitro hERG and in vivo thorough-QT/QT evaluation (ICH S7B/E14) are not warranted, as a subcutaneously administered IgG does not distribute to cardiac ion channels and has no plausible direct electrophysiologic liability. The identified, mechanism-based hazards (immunosuppression with attendant infection risk and, in the reproductive setting, potential B-cell depletion in exposed offspring) are addressed through the clinical risk-management strategy in Section 9.

5. Clinical Pharmacology, Pharmacodynamics, and Immunogenicity

Pharmacokinetics: OBX-319 exhibits pharmacokinetics typical of an IgG monoclonal antibody with a target-mediated component. Following subcutaneous administration, absorption proceeds with the bioavailability characteristic of IgG, and disposition is largely confined to plasma and interstitial fluid. Elimination occurs by nonspecific proteolytic catabolism and, at lower concentrations, by target-mediated drug disposition (TMDD) via binding to CD19/CD20 on B cells, producing non-linear pharmacokinetics in the low-concentration range. Classical small-molecule ADME assessments (mass balance, cytochrome P450 and transporter studies) are not applicable to an intact antibody. A population pharmacokinetic model is being developed to describe the linear and target-mediated clearance components and to support exposure–response characterization for both efficacy and safety.

Pharmacodynamics and biomarkers: OBX-319 produces rapid, near-complete depletion of circulating CD19+ B cells, with mean peripheral counts falling from approximately 210 cells/µL at baseline to approximately 7 cells/µL on active treatment, while placebo counts remain essentially unchanged. This target-engagement signal is accompanied by reductions in anti-double-stranded DNA (anti-dsDNA) antibodies and by normalization of complement C3 and C4 in responding subjects, providing a coherent, mechanism-consistent pharmacodynamic package that links target engagement to the serologic hallmarks of SLE activity. These data underpin the selection of the two dose levels carried forward into OBX319-301 and will be used to support the exposure–response justification of the dose regimen.

Immunogenicity: as an exogenous therapeutic protein, OBX-319 carries an expected potential for anti-drug antibody (ADA) formation. A tiered, validated bioanalytical strategy (screening, confirmatory, titer, and neutralizing-antibody assays) is applied in accordance with ICH M10, and the impact of ADA on exposure, pharmacodynamics, efficacy, and safety (including injection reactions) is being characterized and will be summarized in Module 2.7.2. The Sponsor requests Agency input on the immunogenicity assessment and reporting strategy for the pivotal study.

6. Phase 2 Results Supporting the Pivotal Design

The Phase 2 dose-ranging study in moderate-to-severe active SLE established the dose levels and the endpoint framework carried into OBX319-301. Across the evaluated regimens, OBX-319 produced the profound peripheral B-cell depletion described in Section 5, together with dose-related improvement in SLEDAI-2K disease activity and the expected serologic changes (falling anti-dsDNA and recovering C3/C4) in the higher-exposure groups relative to placebo, on a background of standard-of-care therapy. The safety experience was consistent with the pharmacologic class, dominated by infections (predominantly upper-respiratory and urinary-tract events) and by injection-site reactions, without an unexpected organ-toxicity signal. These findings support a two-dose confirmatory design (High and Low) that brackets the exposure–response relationship and allows the Agency and Sponsor to characterize the dose dependence of both benefit and the class-related infection risk.

7. Proposed Pivotal Study OBX319-301

Design. OBX319-301 is a Phase 3, randomized, double-blind, placebo-controlled study with 1:1:1 allocation to OBX-319 High, OBX-319 Low, and Placebo, each administered subcutaneously on a background of standard-of-care therapy over a 52-week treatment period.

Population. Adults with moderate-to-severe active SLE, with a target baseline disease activity of approximately SLEDAI-2K 11, enrolled against pre-specified serologic and clinical activity criteria. The planned sample size is 480 randomized subjects (approximately 160 per arm), drawn from approximately 900 screened.

Dosing and schedule. Two fixed subcutaneous dose levels (High and Low) versus matching placebo, with assessments at Weeks 0, 4, 12, 24, 36, and 52.

Endpoints. The proposed primary endpoint is SRI-4 response at Week 52, operationalized as attainment of low disease activity defined by SLEDAI-2K ≤ 4. Key secondary endpoints include the change from baseline in SLEDAI-2K at Week 52, corticosteroid tapering, time to and rate of disease flare, and the pharmacodynamic/serologic measures (CD19+ B-cell counts, anti-dsDNA, complement C3/C4). The Sponsor requests Agency agreement that SRI-4 response at Week 52 is an acceptable primary endpoint to support registration in this population.

8. Statistical Considerations and Estimand Strategy

The statistical framework follows ICH E9(R1). For the primary objective, a treatment-policy estimand compares each active dose with placebo: the population is all randomized subjects with a baseline and at least one post-baseline assessment (Full Analysis Set); the variable is SRI-4 response (low disease activity, SLEDAI-2K ≤ 4) at Week 52; intercurrent events, including initiation of rescue or prohibited medication and treatment discontinuation, are handled under the treatment-policy strategy so that the estimand reflects the effect of the treatment regimen as it would be used in practice.

The primary analysis of the continuous SLEDAI-2K endpoint is an ANCOVA of change from baseline at Week 52 with treatment and baseline as covariates; the responder analysis reports risk differences versus placebo with normal-approximation 95% confidence intervals. Missing data are handled under a Missing-At-Random assumption with pre-specified sensitivity analyses (including tipping-point and reference-based approaches) to assess robustness to the missingness assumption. Type-I error is controlled two-sided at α = 0.05 with 0.90 power for the primary comparison; a pre-specified hierarchical/graphical testing procedure controls the family-wise error rate across the two active-dose comparisons and the ordered key secondary endpoints. The Sponsor requests concurrence on the estimand definition, the handling of intercurrent events, and the multiplicity strategy.

9. Safety Database and Risk-Management Plan

Size and duration. Because OBX-319 is intended for chronic use in a non-life-threatening condition, the pre-marketing safety database is being sized to satisfy the exposure expectations of ICH E1 for the assessment of longer-term, lower-frequency events, with the 52-week controlled exposure in OBX319-301 supplemented by continued open-label follow-up. The Sponsor requests Agency agreement that the proposed exposure (number of subjects treated, and the number treated for 6 and 12 months) is adequate to support the application.

Identified and potential risks of B-cell depletion. The key identified risks for this mechanism are serious and opportunistic infections and hypogammaglobulinemia; these, rather than any thyroid or medullary-thyroid-carcinoma consideration (which is a GLP-1-receptor-agonist class effect and is not applicable to a B-cell-depleting antibody), define the core of the risk-management strategy. The plan includes: screening for and management of latent and chronic infections before dosing (including hepatitis B and tuberculosis) with monitoring for reactivation; serial monitoring of serum immunoglobulins (in particular IgG) with pre-specified management guidance for hypogammaglobulinemia; vigilance for opportunistic infection, including consideration of progressive multifocal leukoencephalopathy as a labeled class consideration for B-cell-depleting agents; and immunization guidance advising completion of indicated vaccinations before initiation and avoidance of live vaccines during periods of B-cell depletion.

Administration-related and immunogenicity risks. Injection-site and injection-related reactions and immunogenicity (ADA) are expected, mechanism- and modality-based effects and are addressed through observation-period requirements, standardized reaction reporting, and the tiered ADA strategy of Section 5.

These elements are carried into the Risk Management Plan / risk-evaluation framework, and the Sponsor requests Agency input on whether the routine pharmacovigilance and risk-minimization measures proposed are sufficient or whether additional measures are expected.

10. CMC Considerations for a CHO-Derived Bispecific Antibody

Manufacturing and control follow the platform expectations for a recombinant monoclonal antibody, with additional controls specific to a bispecific molecule. The drug substance is produced by CHO cell culture and purified through a Protein A capture step followed by polishing chromatography and orthogonal viral clearance, with adventitious- and endogenous-virus safety evaluated per ICH Q5A(R2). Stability is established per ICH Q5C, and the specification is set per ICH Q6B, encompassing identity, content, purity and impurity profile (including aggregates, host-cell protein, and residual DNA), charge and glycosylation variants, and potency by a dual-target binding assay together with a functional (B-cell-depletion/effector) bioassay.

Bispecific-specific quality attributes — correct chain pairing, control of mispaired species and half-antibody, and confirmation of simultaneous dual-antigen binding — are defined as part of the control strategy and linked to the potency and purity methods. A comparability strategy per ICH Q5E governs any manufacturing changes between the clinical and commercial processes. Because the product is a subcutaneous presentation, the container-closure and any delivery-device considerations are addressed as part of the combination-product controls. The Sponsor requests Agency alignment on the potency-assay strategy for a bispecific and on the comparability expectations bridging clinical to commercial material.

11. Questions for the Agency

1. Does the Agency agree that the completed nonclinical program — conducted in the cynomolgus monkey as the sole pharmacologically relevant species per ICH S6(R1), and omitting standard genotoxicity, carcinogenicity, and hERG/thorough-QT evaluation as not warranted for this modality — adequately supports the proposed pivotal study and the planned BLA?
2. Does the Agency agree that SRI-4 response at Week 52, operationalized as low disease activity (SLEDAI-2K ≤ 4), is an acceptable primary endpoint to support registration in moderate-to-severe active SLE?
3. Does the Agency concur with the treatment-policy estimand, the handling of intercurrent events, the Missing-At-Random primary analysis with reference-based/tipping-point sensitivity analyses, and the hierarchical multiplicity strategy across the two active doses and key secondary endpoints?
4. Does the Agency agree that the proposed two-dose (High and Low), 1:1:1, 52-week, placebo-controlled design in 480 randomized subjects on background standard-of-care is adequate as the single pivotal confirmatory study?
5. Does the Agency agree that the proposed size and duration of the pre-marketing safety database are adequate to characterize the class risks of serious/opportunistic infection and hypogammaglobulinemia for chronic use?
6. Does the Agency concur with the proposed immunogenicity (ADA) assay strategy and reporting under ICH M10, and with the population-PK/exposure–response approach to justify the dose regimen?
7. Does the Agency agree with the proposed risk-management approach (infection screening and monitoring, immunoglobulin monitoring, vaccination guidance, and injection-reaction management) as sufficient routine and additional pharmacovigilance for this mechanism?
8. Does the Agency agree with the CMC control strategy for a CHO-derived bispecific antibody, including the dual-target/functional potency approach and the comparability plan under ICH Q5A(R2), Q5C, Q6B, and Q5E?